Abstract: Embodiments are directed to a metal-ligand complex catalyst precursor, (L1)(L2)X(R1)(R2), and methods for producing the same from a compound of formula Q2X(R1)(R2). L1 and L2 are independently —R3—Z1 or —R4—Z1. R1 and R2 are independently selected from a hydrogen atom, (C1-C40)hydrocarbyl and, optionally, R1 and R2 are connected to form a ring having from 3 to 50 atoms in the ring, excluding hydrogen atoms. X is Si, Ge, Sn, or Pb. Each Q is independently Ar1—Y1R3— or Ar2—Y2—R4—. R3 and R4 are independently selected from —(CRC2)m—, where m is 1 or 2, and where each RC is independently selected from the group consisting of (C1-C40)hydrocarbyl, (C1-C40)heterohydrocarbyl, and —H. Y1 and Y2 are independently S, Se, or Te. Ar1 and Ar2 are independently (C6-C50)aryl. Ar1—Y1—R3— and Ar2—Y2—R4— are not identical. Each Z1 is independently selected from Cl, Br, and I.

Abstract: This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

Abstract: The present disclosure provides a method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules at a concentration Cfinal (mg/mL). The method comprising the steps of: a) crosslinking a glycosaminoglycan having a molecular weight of above 700 kDa in conditions so as to provide a glycosaminoglycan hydrogel crosslinked by amide bonds and having a Cmin (mg/mL) that is above Cfinal/2, wherein Cmin is the concentration of gel-form glycosaminoglycan in the gel when fully swollen in physiological buffer; b) subjecting the hydrogel from step a) to post-crosslinking degradation of the glycosaminoglycan backbone, thereby reducing the Cmin of the hydrogel to a value that is below Cfinal/2; and c) formulating the partially degraded hydrogel obtained from step b) to form an injectable hydrogel composition having a concentration of glycosaminoglycan molecules of Cfinal (mg/mL).

Abstract: The present invention relates to a composition, for preventing or treating a fine dust-induced respiratory disease, comprising a mixture (Rgx 365), comprising ginsenosides Rg2, Rg4, Rg6 and Rh1, as an active ingredient, a preparation method thereof, and a functional health food, for preventing or relieving a fine dust-induced respiratory disease, comprising same. The present invention exhibits excellent effects on permeability reduction, reactive oxygen (ROS) generation reduction, leucocyte reduction and cytokine generation reduction in a model for fine dust-induced inflammatory response, and thus can be utilized for preventing and treating a fine dust-induced respiratory disease.

Abstract: The present technology relates to a method of separating a sample comprising oligonucleotides. The method includes injecting a polyphosphonic acid at a concentration of between about 0.01 M to about 1 M into the sample comprising oligonucleotides. The method also includes flowing the sample and polyphosphonic acid through a liquid chromatography column and separating the oligonucleotides.

Abstract: Various methods and compositions for treating age-associated conditions and other medical conditions, such as muscle diseases, type 2 diabetes, and/or obesity are described. Methods of enhancing cellular uptake of NMN and stimulating NAD+ production are further described. Various mammalian cells and mammalian cell lines are described including those comprising a cDNA encoding a Slc12a8 protein. Gene therapy vectors comprising a nucleic acid encoding Slc12a8 and non-human animals comprising an inactivating mutation in a Slc12a8 gene are also disclosed. Also described are methods for screening a candidate compound to identify compounds that promote NMN transport.

Abstract: The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.

Abstract: Provided herein are bifunctional compounds with a moiety or domain that is a binder of the ubiquitin receptor RPN13 and another moiety or domain that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one domain of the bifunctional compound is a binder of the ubiquitin receptor RPN13 and another domain of the compound is a binder of the target protein DOT1L in a subject.

Abstract: Provided herein are photochemical separations. The methods herein can include exposing a first metal complex and a second metal complex to light to facilitate an irreversible chemical reaction to form a modified first metal complex. The modified first metal complex then may be separated from the second metal complex. Compositions also are provided.

Abstract: A process for the preparation of high purity norbornene alkyl silyl ether is disclosed and claimed. Specifically, a process for the preparation of industrial scale high purity norbornene methyl silyl ether is disclosed and claimed. The high purity monomers prepared in accordance with the process of this invention are useful in a variety of applications including but not limited to the preparation of high quality and high purity polynorbornenes having utility in a variety of electronic applications, among various other applications.

Abstract: The present disclosure further relates to a linker-payload compound including an oligosaccharide group, especially a disaccharide group, where the oligosaccharide group is linked to the remainder of the compound by an amide bond. The present disclosure further relates to an antibody-drug conjugate (ADC) containing the linker-payload compound, where the glycan chain in an antibody is remodeled with the oligosaccharide moiety in the linker-payload compound. The present disclosure further relates to preparation methods and use of the above-mentioned substances.

Abstract: The present invention discloses a crystal form, a preparation method and an application of a 4?-substituted nucleoside compound I having the following structure, including salts, prodrugs, and compositions thereof. Animal pharmacokinetic studies demonstrated that the effective drug concentrations of Compound Ia and Compound Ig in HIV target cells, peripheral blood mononuclear cells (PBMC), were effective in inhibiting HIV replication after 7 and 5 days, respectively. Therefore, Compound I can be used as a long-acting drug for preventing and treating AIDS. R is selected from ethynyl, azide, and cyano groups, X is selected from hydrogen and fluorine, and B is selected from B1 and B2.

Abstract: A process for preparing trimethylchlorosilane (M3) and methyltrichlorosilane (M1) by disproportionation of dimethyldichlorosilane (M2) in the presence of an Al2O3 catalyst is described herein. The dimethyldichlorosilane used is in the form of a silane mixture that includes 80-100% by weight of dimethyldichlorosilane (M2). The difference in content from 100% by weight includes M1 and M3.

Abstract: A treatment for reducing glucose bioaccessibility can include providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together. The superabsorbent material can be administered to a subject in an effective amount to reduce glucose bioaccessibility in the subject. In some aspects, the treatment for reducing glucose bioaccessibility with the superabsorbent material retains a substantially unaltered fatty acid bioaccessibility and/or retains a substantially unaltered protein bioaccessibility.

Abstract: A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containing the mixture, and uses thereof serving as an intrinsic factor X-enzyme (Xase) inhibitor in the preparation of drugs for preventing and/or treating thrombotic diseases.

Abstract: In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

Abstract: Provided is a method for producing a halogenated hydrocarbon magnesium compound, the method including bringing a halogenated hydrocarbon compound into contact with magnesium having a specific surface area of 1×10?5 to 2×10?4 m2/g. Also provided are methods for producing a tertiary alcohol compound and an organosilicon compound, wherein said production method is utilized.

Abstract: The present invention discloses a dual-drug co-delivery system, a preparation method therefor and use thereof, the dual-drug co-delivery system being prepared from raw materials comprising a block copolymer, Homoharringtonine and Doxorubicin hydrochloride. The dual-drug co-delivery system provided by the present invention has a stronger killing effect on various hematologic tumors and solid tumor cells, can provide a feasible drug delivery system for inhibiting tumor growth and leukemia treatment, and has broad prospects.

Abstract: A method of preparing an organosilicon compound via selective silylation of ethylene is disclosed. The method comrises prises reacting via silylation (A) a hydridochlorosilane compound and (B) ethylene in the presence of (C) a catalyst, thereby preparing the organosilicon compound. The silylation may be selectively conducted as a dehydrogenative coupling to prepare the organosilicon ompound as a vinylchlorosilane compound, or as a hydrosilylation to prepare the organosilicon compound as an ethylchlorosilane compound. The catalyst (C) comprises a Ru(0) complex, and may be recycled for use in subsequent silylation reactions without purification. The organosilicon compound prepared according to the method is also disclosed.